RNA — Avidity Biosciences Share News
0.000.00%
Last trade - 00:00- $11.27bn
- $9.40bn
- $10.90m
Avidity Biosciences rises after boosted $600 mln equity raise
Brief: Avidity Biosciences Prices Upsized Public Offering At $40 Per Share
Avidity Biosciences slides on planned $500 mln stock offering
Brief: Avidity Biosciences Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
Avidity Biosciences rises after positive trial data for muscle wasting drug
Brief: Avidity Biosciences' Del-zota Shows Disease Reversal in Key Endpoints
Avidity Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Press Digest: Financial Times - August 7
U.S. STOCKS ON THE MOVE-Novavax, copper miners, Apple
Avidity Biosciences rises on report of Novartis buyout deal
Novartis weighs deal for biotech Avidity Biosciences, FT reports (updated)
Novartis weighs deal for biotech Avidity Biosciences, FT reports
Brief: Novartis Weighs Deal For Biotech Avidity To Boost Drug Pipeline - FT
Brief: Avidity Biosciences Announces Completion Of Enrollment For HARBOR™, The First Global Phase 3 Trial Of Delpacibart Etedesiran (Del-Desiran) For Treatment Of DM1 And Provides Guidance On Regulatory Submission
Brief: Avidity Biosciences Receives FDA Breakthrough Therapy Designation For Duchenne Muscular Dystrophy Treatment
Brief: Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients
Avidity Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary